Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05243446
Other study ID # ST-4/CELART
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 2015
Est. completion date December 31, 2023

Study information

Verified date February 2022
Source Medical University of Gdansk
Contact Leszek Tylicki, professor
Phone 48583492505
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The influence of Losartan to cardiovascular and renal outcomes in patients after renal transplatation.


Description:

The benefits of cardio and nephroprotective properties of treatment with drugs blocking the renin angiotensin aldosterone system in the general population has already been shown. There are no data on the cardiac and renal effects of this type of treatment in patients after renal transplantation. Therefore, the observational, case-control study was designed in a population of kidney transplant recipients. The study group consists of patients treated with antihypertensive drugs including Losartan at a minimum dose of 50mg. The control group consists of patients treated with antihypertensive drugs, without the renin angiotensin aldosterone system blockade. Blood pressure will be controlled in accordance with the current recommendations. The primary aim of this study is to determine whether, in renal transplant recipients with hypertension, losartan, angiotensin II receptor antagonist improves cardiovascular and graft outcome i.e. reduces incidence of cardiovascular complications and slows progression of graft insufficiency. Secondary objective is to determine whether losartan 1. delays the occurrence of cardiovascular complications, 2. slows progression of graft insufficiency, 3. is the safe drug in renal transplant recipients, 4. decrease albuminuria and other surrogate markers of graft injury or cardiovascular involvement.


Recruitment information / eligibility

Status Recruiting
Enrollment 740
Est. completion date December 31, 2023
Est. primary completion date December 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 740 patients, either sex, either non-diabetic or diabetic who underwent the kidney transplantation and who: 1. Are at least three months post-transplantation 2. Have hypertension. 3. Have an estimated glomerular filtration rate greater than or equal to 30 ml/min/1.73 m2 Exclusion Criteria: 1. Pregnant or the possibility of becoming so and breast feeding. 2. Angioedema from an Angiotensin Converting Enzyme (ACE) inhibitor or Angiotensin Receptor Blocker (ARB) in the history. 3. Serum potassium greater than 5.5 mmol/l on two or more occasions in the preceding three months. 4. Graft artery stenosis (i.e. psv of more than 200 cm/s in doppler usg) 5. Left ventricular dysfunction that requires an ACE inhibitor or an ARB 6. New immunosuppressive agent was started or previous immunosuppressant stopped in the three months prior to study entry or plan to switch immunosuppressive agents within next three months. 7. Currently on four or more blood pressure pills and have an average blood pressure over three visits greater than 150/100. 8. Currently on an ACE-inhibitor or an ARB or treatment with an ACE inhibitor or ARB after kidney transplantation lasted more than 3 months. 9. Had an acute coronary syndrome, episode of malignant hypertension, stroke or transient ischaemic attack in the three months prior to study entry.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Losartan
losartan treatment

Locations

Country Name City State
Poland Medical University Gdansk

Sponsors (9)

Lead Sponsor Collaborator
Medical University of Gdansk Jagiellonian University, Medical University of Bialystok, Medical University of Silesia, Medical University of Warsaw, Nicolaus Copernicus University, Pomeranian Medical University Szczecin, Poznan Regional Hospital, Wroclaw Medical University

Country where clinical trial is conducted

Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Occurrence of composite primary endpoint: Cardiovascular (CV) death and Resuscitated sudden death and Non-fatal myocardial infarction (MI) and Non-fatal stroke and Unplanned hospitalization for heart failure or unstable angina and Onset of end-stage renal disease (ESRD) and Doubling of baseline serum creatinine concentration, sustained for at least one month. Up to 5 years
Secondary Occurrence of cardiovascular complications Cardiovascular (CV) death and Resuscitated sudden death and Non-fatal myocardial infarction (MI) and Non-fatal stroke and Unplanned hospitalization for heart failure or unstable angina Up to 5 years
Secondary Occurrence of renal complications ESRD or doubling of baseline serum creatinine Up to 5 years
Secondary Decline in estimated glomerular filtration rate (eGFR) Difference in degree of eGFR reduction Up to 5 years
Secondary Urine albumine concentration Difference in albuminuria in the measurements available for each patient after 6 months
Secondary N-acetyl-ß-D-glucosaminidase (NAG) urine excretion Difference in urine NAF in the measurements available for each patient after 6 months
Secondary 15-F2t-isoprostanes (isoprostanes) urine excretion differences in 15-F2t-isoprostanes (isoprostanes) urine excretion in the measurements available for each patient after 6 months
See also
  Status Clinical Trial Phase
Completed NCT06089226 - Parameters Related to Physical Activity Level in SCI
Recruiting NCT04696081 - Atrial Fibrillation in Active Cancer Patients
Completed NCT05687097 - Untreated Sleep Apnea as an Aggravating Factor for Other Secondary Medical Conditions After Spinal Cord Injury
Completed NCT03274869 - Scrub Typhus Infection Induced Cardiovascular Disease
Completed NCT04025086 - Perioperative Goal Directed Therapy (PGDT) in Spinal Surgery in the Prone Position
Completed NCT03010969 - Perioperative Endothelial Dysfunction in Patients Undergoing Major Acute Abdominal Surgery
Completed NCT01413815 - Effect of the Amino Acid L-arginine on Perioperative Cardio-vascular Risk in Non-selected Patients N/A
Recruiting NCT05077748 - An 18-year Follow-up Study on OSA in a Population-based Cohort
Not yet recruiting NCT06279000 - Colchicine in Patients at Cardiac Risk Undergoing Major Non-Cardiac Surgery Phase 3
Enrolling by invitation NCT06360666 - Clinical Outcomes in Adult Patients Undergoing Laparoscopic Surgery Under Neuraxial Anesthesia
Recruiting NCT03977337 - Perioperative Pulmonary Monitoring in Major Emergency Surgery
Recruiting NCT05996965 - Evaluation of Clinical Utility of Non-invasive Hemodynamic Monitoring Device
Recruiting NCT05349955 - Effects and Safety of Diabetic GUideline Algorithm Implementation Performed by Primary Care Physicians in the Community N/A
Withdrawn NCT04435015 - The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications Phase 1/Phase 2
Active, not recruiting NCT05745090 - N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) in Type 2 Diabetes Mellitus
Terminated NCT03760159 - Minimally Invasive Detection of a Sleep Apnoea
Completed NCT04802122 - Induction of Anesthesia With Sevoflurane Preserving Spontaneous Breathing: Cardiorespiratory Effects. Phase 4
Not yet recruiting NCT06419270 - Cardiovascular, Renal, and Skeletal Complications in Patients With Post-Surgical Hypoparathyroidism
Recruiting NCT05895669 - Cardiovascular Outcomes in Orthotopic Liver Transplanted Patients (COLT Study)
Completed NCT05685979 - Evaluation of Cardiac Functions in Deep Trendelenburg Position